Lead Product Candidates
RAPID DEVELOPMENT OF BISPECIFIC ANTIBODIES FROM CONCEPT TO INVESTIGATIONAL DRUG
A key differentiator for Imunexus’ technology is the modular nature and the retrofitting capability of imunexinsTM that allows an unprecedented level of flexibility for generating multispecifics from existing antibodies (or other proteins). Imunexus is currently focusing on converting marketed, clinically validated, or advanced preclinical antibodies into multispecifics. This strategy carries key advantages over many other drug discovery and development approaches including:
- The approach gives Imunexus a clear, risk-reduced path forward for creating therapeutic products based on a vast number of commercially validated, clinical, and preclinical antibodies available.
- Due to the ease of fusion and the lack of downstream engineering, the same imunexinsTM module can be “bolted on” to a number of different parent antibodies to rapidly (within months) generate extensive multispecific antibody pipelines.
- Imunexus’ proprietary rapid-screen technology can identify new, target specific ImunexinsTM and convert existing antibodies at a fraction of the cost of traditional antibody discovery.
- The development risks are lower and the clinical pathway is more predictable as the clinical properties of the parent antibody and its therapeutic target are well documented and supported with extensive preclinical and clinical data.
CURRENT LEAD PRODUCTS
Imunexus’ has applied its unique technology to generate a number of therapeutic products (8 in total). In the immediate term, Imunexus intends to advance the development of two therapeutic products and one co-development activity as outlined below:
IMX101 - Bispecific Treatment for Small Cell Lung Cancer (SCLC). Imunexus will continue the development of a bispecific antibody treatment for SCLC. IMX101 is a multispecific antibody that utilizes an imunexinsTM that activates the immune system fused to a SCLC specific parent antibody. Imunexus intends to finalise IMX101 lead and undertake manufacturing and move towards a phase I / IIa clinical trial for the treatment of SCLC. SCLC is an important disease and unmet medical need with a poor prognosis and sub-optimal current therapies resulting in a very low survival rate.
IMX110 - Bispecific Treatment for Colorectal cancer(CRC). Quickly following on from its IMX101 bispecific antibody for SCLC, the Company is developing a second, different bispecific antibody for the treatment of CRC that utilizes a half-life extending imunexinsTM fused to a colorectal cancer specific parent antibody. CRC ranks as the third most common cancer worldwide, with approximately 1 million new cases diagnosed annually. Imunexus will complete its animal studies and commence manufacturing with the intention of scale up and move towards a phase I clinical trial for the treatment of colorectal cancer.
Imunexin Mediated Targeting of Mesenchymal Stem Cells. Imunexus’ recent (patent pending) technology (PCT is in draft) utilises the Company’s imunexin technology to add a new therapeutic utility to many mammalian cells including mesenchymal stem cells (MSCs). Adding imunexins to the cell surface of MSC’s, for example, allows for specific MSC targeting to specific therapeutic targets or diseased cells. Imunexus will continue to develop imunexin applications with mesenchymal stem cells with a partner.
Additional Pipeline Products: Along with the immediate term development of IMX101 and IMX110, in the medium term, Imunexus plans are to continue to develop its other bispecific antibody products for the treatment of a number of oncology and autoimmune diseases. Imunexus’ pipeline contains eight potential products, including Imunexus Products IMX101 and IMX110. Note that the pipeline of additional Imunexus Products IMX102 (lymphoblastic leukaemia), 103 (breast cancer), 104 (non-Hodgkin's lymphoma), 105 (ovarian cancer), 106 (ankylosing spondylitis) and 110 (colorectal cancer) are bispecifics based on commercial antibodies (off-patent and at no cost to Imunexus). Imunexus Product IMX101 is based on an advanced preclinical antibody. IMX107 (extreme peanut anaphylaxis) is a proprietary non-antibody based bispecific.